Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.
Also called NCT02752113
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 101 participants
- Registry
-
NCT02752113 -
2016-000242-57
-
- Other papers using this trial's data
- Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes
- Is GFR decline induced by SGLT2 inhibitor of clinical importance?
- Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT02752113. Randomized; no masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2018-11-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
- Acronym
- ELMI
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- Empagliflozin and Linagliptin
- Intervention (Drug)
- Metformin and Insulin sc
- Lead sponsor
- Institut für Pharmakologie und Präventive Medizin
- Collaborator
- University of Erlangen-Nürnberg Medical School
Record details
- Record id
cardio:ct-nct02752113- Content hash
1a56f6388ae63292b776f059be8f6a9964c184d64ef9617f03753a7b2ff5025c